Inhibitory mechanisms of celastrol on human liver cytochrome P450 1A2, 2C19, 2D6, 2E1 and 3A4

被引:30
|
作者
Jin, Chunhuan [1 ]
He, Xin [1 ,2 ]
Zhang, Fangliang [1 ]
He, Lina [1 ]
Chen, Junxiu [1 ]
Wang, Lili [1 ,2 ]
An, Lijun [1 ]
Fan, Yaowen [1 ]
机构
[1] Tianjin Univ Tradit Chinese Med, Sch Chinese Mat Med, Tianjin 300193, Peoples R China
[2] Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China
基金
中国国家自然科学基金;
关键词
CYP; herb-drug interaction (HDI); inhibition; in vitro; IN-VITRO; ENZYMES; MICROSOMES; OXIDATION; DRUGS;
D O I
10.3109/00498254.2014.1003113
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The present study was conducted to examine the possibility of herb-drug interaction by celastrol, which is a main compound isolated from Tripterygium wilfordii Hook F. using human liver microsomes with cocktail methods. Focused on its inhibitory manner on the metabolism of model probe substrates of five cytochrome P450 isoenzymes (CYP1A2, CYP2C19, CYP2D6, CYP2E1 and CYP3A4) in vitro which are important with the metabolism of different xenobiotics. 2. The results showed that celastrol inhibited the five types of human cytochrome P450 isoforms, with the IC50 values of 2.65 mu M (CYP3A4), 5.99 mu M (CYP2C19), 6.27 mu M (CYP2D6), 7.66 mu M (CYP1A2) and 9.38 mu M (CYP2E1), respectively. The data indicated that celastrol acted in different manners as an inhibitor of human cytochrome P450 isoforms, which showed that celastrol not only un-competitively inhibited the CYP1A2 and 2E1 activities, but also competitively inhibited the CYP2C19 and 2D6 activities with K-i values of 1.41, 2.29, 5.27 and 4.21 mM, respectively. Celastrol was also a mixed-type inhibitor of CYP3A4, with K-i and K-is values of 2.02 and 5.49 mu M, respectively. 3. Celastrol has the potential to inhibit cytochrome P450 activities and may cause the herbdrug interactions. Therefore, the use of celastrol and its preparations with conventional medicines should thus be taken in to account.
引用
收藏
页码:571 / 577
页数:7
相关论文
共 50 条
  • [41] BUFURALOL HYDROXYLATION BY CYTOCHROME-P450 2D6 AND 1A2 ENZYMES IN HUMAN LIVER-MICROSOMES
    YAMAZAKI, H
    GUO, ZY
    PERSMARK, M
    MIMURA, M
    INOUE, K
    GUENGERICH, FP
    SHIMADA, T
    MOLECULAR PHARMACOLOGY, 1994, 46 (03) : 568 - 577
  • [42] Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone
    Shou, MG
    Korzekwa, KR
    Brooks, EN
    Krausz, KW
    Gonzalez, FJ
    Gelboin, HV
    CARCINOGENESIS, 1997, 18 (01) : 207 - 214
  • [43] Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1
    Blakey, GE
    Lockton, JA
    Perrett, J
    Norwood, P
    Russell, M
    Aherne, Z
    Plume, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (02) : 162 - 169
  • [44] Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1
    Garton, KJ
    Yuen, P
    Meinwald, J
    Thummel, KE
    Kharasch, ED
    DRUG METABOLISM AND DISPOSITION, 1995, 23 (12) : 1426 - 1430
  • [45] The Role of Human Cytochrome P450 2E1 in Liver Inflammation and Fibrosis
    Xu, Jun
    Ma, Hsiao-Yen
    Liang, Shuang
    Sun, Mengxi
    Karin, Gabriel
    Koyama, Yukinori
    Hu, Ronglin
    Quehenberger, Oswald
    Davidson, Nicholas O.
    Dennis, Edward A.
    Kisseleva, Tatiana
    Brenner, David A.
    HEPATOLOGY COMMUNICATIONS, 2017, 1 (10) : 1043 - 1057
  • [46] Enzyme Kinetics and Molecular Docking Studies on Cytochrome 2B6, 2C19, 2E1, and 3A4 Activities by Sauchinone
    Gong, Eun Chae
    Chea, Satya
    Balupuri, Anand
    Kang, Nam Sook
    Chin, Young-Won
    Choi, Young Hee
    MOLECULES, 2018, 23 (03):
  • [47] Lysophosphatidylserine-induced functional switch of human cytochrome P450 1A2 and 2E1 from monooxygenase to phospholipase D
    Cho, Eun Yi
    Yun, Chul-Ho
    Chae, Ho-Zoon
    Chae, Han-Jung
    Ahn, Taeho
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 376 (03) : 584 - 589
  • [48] Nefiracetam metabolism by human liver microsomes: role of cytochrome P450 3A4 and cytochrome P450 1A2 in 5-hydroxynefiracetam formation
    Fujimaki, Y
    Arai, N
    Nakazawa, T
    Fujimaki, M
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (06) : 795 - 804
  • [49] Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population
    Aynacioglu, AS
    Sachse, C
    Bozkurt, A
    Kortunay, S
    Nacak, M
    Schröder, T
    Kayaalp, SO
    Roots, I
    Brockmöller, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (02) : 185 - 192
  • [50] Genetic polymorphism of human cytochrome P450 2E1
    Nedelcheva, V
    Persson, I
    IngelmanSundberg, M
    CYTOCHROME P450, PT B, 1996, 272 : 218 - 225